3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
CNS
1
Conditions
Venous Thromboembolism
17
Neoplasms
11
Venous Thrombosis
7
Pulmonary Embolism
7
Thrombosis
5
Multiple Myeloma
4
Upper Extremity Deep Vein Thrombosis
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Myeloproliferative Disorders
2
Intracranial Thrombosis
2
Hematologic Neoplasms
2
Carcinoma, Hepatocellular
2
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thromboprophylaxis
1
Thromboembolism
1
Thrombocytopenia
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Ovarian Neoplasms
1
Neoplasms, Plasma Cell
1
Mesenteric Ischemia
1
Lymphoma
1
Leukemia
1
Head and Neck Neoplasms
1
Glioma
1
Interventions
Temozolomide
61
Radiotherapy
25
Bevacizumab
21
Magnetic Resonance Spectroscopy
20
Irinotecan
18
Filgrastim
15
Carboplatin
15
Carmustine
11
Surgical Procedures, Operative
10
Etoposide
9
antineoplaston AS 2-1
8
antineoplaston A10
8
Specimen Handling
8
sargramostim
7
Radiation
7
Peripheral Blood Stem Cell Transplantation
7
Everolimus
7
Biopsy
7
Vincristine
6
Radiotherapy, Intensity-Modulated
6
Procarbazine
6
O(6)-benzylguanine
6
Erlotinib Hydrochloride
6
Topotecan
5
Melphalan
5
Magnetic Resonance Imaging
5
Lomustine
5
Genetic Therapy
5
Cyclophosphamide
5
Aminolevulinic Acid
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Astrocytoma
×
apixaban
×
Clear all
NCT05683808
2026-01-30
VTE-POG
University of Vermont Medical Center
Phase 2
Recruiting
40 enrolled